Literature DB >> 31138932

Alzheimer disease and aducanumab: adjusting our approach.

Dennis J Selkoe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31138932     DOI： 10.1038/s41582-019-0205-1

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  65 in total

Review 1.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

Review 2.  Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease.

Authors:  Matan B Abou; Liang Sun; Huafeng Wei
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

3.  Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.

Authors:  Crystal M Vander Zanden; Eva Y Chi
Journal:  J Pharm Sci       Date:  2019-10-21       Impact factor: 3.534

4.  Advances in Drug Therapy for Alzheimer's Disease.

Authors:  Chuan-Cong Zhu; Si-Yu Fu; Yu-Xin Chen; Ling Li; Ruo-Lin Mao; Jian-Zhi Wang; Rong Liu; Yi Liu; Xiao-Chuan Wang
Journal:  Curr Med Sci       Date:  2021-01-11

5.  Targeting Hsc70-based autophagy to eliminate amyloid β oligomers.

Authors:  Juan Dou; Peng Su; Chongchong Xu; Zhexing Wen; Zixu Mao; Wenming Li
Journal:  Biochem Biophys Res Commun       Date:  2020-02-11       Impact factor: 3.575

6.  Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients.

Authors:  Pradeep K Singh; Zu-Lin Chen; Dhiman Ghosh; Sidney Strickland; Erin H Norris
Journal:  Neurobiol Dis       Date:  2020-03-12       Impact factor: 5.996

7.  Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease.

Authors:  James M Wilkins; Brent P Forester
Journal:  Int J Geriatr Psychiatry       Date:  2020-01-26       Impact factor: 3.485

8.  Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment.

Authors:  Axel Montagne; Mikko T Huuskonen; Gautham Rajagopal; Melanie D Sweeney; Daniel A Nation; Farshid Sepehrband; Lina M D'Orazio; Michael G Harrington; Helena C Chui; Meng Law; Arthur W Toga; Berislav V Zlokovic
Journal:  Alzheimers Dement       Date:  2019-12       Impact factor: 21.566

9.  Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.

Authors:  Yujie Chen; Guanghong Wei; Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  ACS Chem Neurosci       Date:  2020-10-09       Impact factor: 4.418

Review 10.  Amyloid-β: a potential link between epilepsy and cognitive decline.

Authors:  Michele Romoli; Arjune Sen; Lucilla Parnetti; Paolo Calabresi; Cinzia Costa
Journal:  Nat Rev Neurol       Date:  2021-06-11       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.